National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Cladribine (Mavenclad®) for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features

NCPE Assessment Process Ongoing
Rapid review received  22/08/2017
Rapid review completed  18/09/2017
Rapid Review outcome A Full pharmacoeconomic assessment is recommended
Full pharmacoeconomic assessment commissioned by HSE  03/10/2017
Pre-submission consultation with Applicant  24/10/2017
Submission received from Applicant  20/12/2017
NCPE assessment commenced 02/01/2018
Preliminary review sent to Applicant 09/02/2018
Preliminary response received from Applicant 01/03/2018
NCPE assessment re-commenced 02/03/2018
Current Status NCPE assessment ongoing